ნოვარტისი (NOTA) Stock Price & News

Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024. Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others. Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, novae artes. After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Wikipedia

About ნოვარტისი

CEOვასანტ ნარასიმჰანი

Employees75,3 ათ.

Founded7 მარ. 1996

Headquartersბაზელი, ბაზელ-შტადტის კანტონი, შვეიცარია

SectorPharmaceutical industry

Websitenovartis.com

Revenue

Net income

All values in USD	სექ. 2025	დეკ. 2025	მარ. 2026	ივნ. 2026
Revenue	14,36 მლრდ.	13,86 მლრდ.	13,52 მლრდ.	14,95 მლრდ.
Cost of goods sold	3,54 მლრდ.	3,54 მლრდ.	3,44 მლრდ.	3,68 მლრდ.
Cost of revenue	3,54 მლრდ.	3,54 მლრდ.	3,44 მლრდ.	3,68 მლრდ.
Research and development expenses	2,86 მლრდ.	2,84 მლრდ.	2,78 მლრდ.	2,74 მლრდ.
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	3,30 მლრდ.	3,44 მლრდ.	3,14 მლრდ.	3,23 მლრდ.
Operating expense	6,24 მლრდ.	6,46 მლრდ.	5,96 მლრდ.	6,10 მლრდ.
Total operating expenses	9,77 მლრდ.	10,00 მლრდ.	9,40 მლრდ.	9,78 მლრდ.
Operating income	4,58 მლრდ.	3,86 მლრდ.	4,12 მლრდ.	5,18 მლრდ.
Other non operating income	-7,00 მლნ.	-130,00 მლნ.	4,00 მლნ.	19,00 მლნ.
EBT including unusual items	4,20 მლრდ.	3,22 მლრდ.	3,84 მლრდ.	4,27 მლრდ.
EBT excluding unusual items	4,29 მლრდ.	3,49 მლრდ.	3,78 მლრდ.	4,73 მლრდ.
Income tax expense	266,00 მლნ.	814,00 მლნ.	683,00 მლნ.	1,01 მლრდ.
Effective tax rate	6,34%	25,30%	17,79%	23,71%
Other operating expenses	70,00 მლნ.	190,00 მლნ.	42,00 მლნ.	127,00 მლნ.
Net income	3,93 მლრდ.	2,41 მლრდ.	3,16 მლრდ.	3,26 მლრდ.
Net profit margin	27,36%	17,38%	23,34%	21,83%
Earnings per share	2,25	2,03	1,99	2,41
Interest and investment income	-	373,00 მლნ.	-	-
Interest expense	-281,00 მლნ.	-304,00 მლნ.	-343,00 მლნ.	-462,00 მლნ.
Net interest expenses	-281,00 მლნ.	69,00 მლნ.	-343,00 მლნ.	-462,00 მლნ.
Depreciation and amortization charges	-	-	-	-
EBITDA	5,78 მლრდ.	4,96 მლრდ.	5,24 მლრდ.	6,30 მლრდ.
Gain or loss from assets sale	81,00 მლნ.	80,00 მლნ.	-159,00 მლნ.	-247,00 მლნ.

Ask anything